Turnstone Biologics Corp.
TSBXHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY24 | FY23 | FY22 | |
|---|---|---|---|
| Revenue | — | $19.3M | $73.3M |
| Operating income | −$72.5M | −$59.0M | −$31.6M |
| Net income | −$70.8M | −$55.2M | −$30.8M |
| Total assets | $40.1M | $112.8M | $114.9M |
| Total liabilities | $8.7M | $14.1M | $44.5M |
| Equity | $31.5M | $98.7M | −$101.5M |
| EPS (diluted) | $-3.07 | $-4.78 | $-12.49 |
| Shares out. | 23.1M | 23.1M | 2.9M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2024- Operating margin
- —
- Net margin
- —
- Return on equity
- −225.1%
- Return on assets
- −176.5%
- Return on capital (ROCE)
- −227.0%
- Liabilities / assets
- 21.6%
- Debt / equity
- 0.28×
- Book value / share
- $1.36
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2024- Altman Z″ (distress)
- -24.18distress
- Accruals / assets
- −8.5%clean
- Piotroski F-Score
- 2/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| Jul 31, 2025 | 258,654 | 2.8 | -8.1% |
| Jul 15, 2025 | 281,355 | 1.7 | -15.9% |
| Jun 30, 2025 | 334,611 | 1.0 | -22.2% |
| Jun 13, 2025 | 430,090 | 1.0 | +168.6% |
| May 30, 2025 | 160,154 | 3.2 | -47.7% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsAug 11, 2025
- Entered a material agreement · Terminated a material agreement · Director / officer change · Regulation FD disclosureJun 27, 2025
- Results of operationsMay 9, 2025
- Delisting / listing-standard noticeApr 1, 2025
- Results of operationsMar 31, 2025
- Regulation FD disclosure · Other material eventFeb 4, 2025
- Results of operationsNov 12, 2024
- Costs from exit or disposal · Director / officer change · Regulation FD disclosureOct 11, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.